Minerva Neurosciences (NERV) Change in Accured Expenses (2013 - 2026)
Minerva Neurosciences (NERV) posted Change in Accured Expenses of $796544.0 for Q1 2026, up 646.07% on a QoQ basis from -$145868.0 in Q4 2025, and up 918.3% year-over-year from $78223.0 in Q1 2025.
Minerva Neurosciences (NERV) Change in Accured Expenses (2013 - 2026) Analysis & Trends
Minerva Neurosciences' Change in Accured Expenses history runs 14 years deep, the most recent figure standing at $796544.0 for Q1 2026.
- Quarterly Change in Accured Expenses rose 918.3% year-over-year to $796544.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.0 million (up 1276.95% YoY) and the FY2025 annual result came in at $317446.0, up 203.71% from the prior year.
- Change in Accured Expenses was $796544.0 for Q1 2026 at Minerva Neurosciences, up from -$145868.0 in the prior quarter.
- Across five years, Change in Accured Expenses topped out at $2.0 million in Q2 2024 and bottomed at -$2.7 million in Q4 2024.
- A 5-year average of $81014.8 and a median of $78223.0 in 2025 frame the typical range for Change in Accured Expenses.
- Peak annual rise in Change in Accured Expenses reached 2773.82% in 2024, while the deepest fall reached 543.84% in 2024.
- Minerva Neurosciences' Change in Accured Expenses stood at -$1.3 million in 2022, then surged by 66.6% to -$419493.0 in 2023, then tumbled by 543.84% to -$2.7 million in 2024, then soared by 94.6% to -$145868.0 in 2025, then surged by 646.07% to $796544.0 in 2026.
- Business Quant data shows NERV's Change in Accured Expenses at $796544.0 in Q1 2026, -$145868.0 in Q4 2025, and $60255.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 1.13 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | -16.82 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 23.10 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 107.70 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -16.74 Mn |
| 10 | Minerva Neurosciences | 195.10 Mn | 195.10 Mn | - | 796,544.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 796,544.00 |
| Mar 31, 2026 | 796,544.00 |
| Dec 31, 2025 | -145,868.00 |
| Dec 31, 2025 | -145,868.00 |
| Sep 30, 2025 | 60,255.00 |
| Sep 30, 2025 | 60,255.00 |
| Jun 30, 2025 | 324,836.00 |
| Jun 30, 2025 | 324,836.00 |
| Mar 31, 2025 | 78,223.00 |
| Mar 31, 2025 | 78,223.00 |
| Dec 31, 2024 | -2.70 Mn |
| Dec 31, 2024 | -2.70 Mn |
| Sep 30, 2024 | 554,787.00 |
| Sep 30, 2024 | 554,787.00 |
| Jun 30, 2024 | 1.98 Mn |
| Jun 30, 2024 | 1.98 Mn |
| Mar 31, 2024 | -139,870.00 |
| Mar 31, 2024 | -139,870.00 |
| Dec 31, 2023 | -419,493.00 |
| Dec 31, 2023 | -419,493.00 |